Skip to main content
2024 ACRO Annual Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Physician

Resident

NewPractitioner

Session: LUNG: Common and Uncommon Emerging Indications for Thoracic Cancers

1 - Managing Challenging Early Stage NSCLC Cases and Exploring the Combination of Stereotactic Ablative Radiotherapy and Immunotherapy

Saturday, March 16, 2024
8:30 AM – 9:30 AM ET
Location: Grand Ballroom VI-VIII

    Speaker(s)

  • Joe Chang, MD

    Professor
    MD Anderson Cancer Center Houston

    Disclosure(s): BMS: Grant/Research Support (Ongoing); IBA: Consultant/Advisory Board (Ongoing); Regeneron: Consultant/Advisory Board (Ongoing)

    PDF Slides
Disclosure(s):
Joe Chang, MD: BMS: Grant/Research Support (Ongoing); IBA: Consultant/Advisory Board (Ongoing); Regeneron: Consultant/Advisory Board (Ongoing)

Learning Objectives:

  • Interpret the clinical outcomes of stereotactic ablative radiotherapy (SABR) in early-stage NSCLC as compared with conventional radiotherapy or surgical resection
  • Illustrate the potentials and challenges of SABR
  • Demonstrate the clinical benefit of additional immunotherapy with SABR (I-SABR) in early-stage NSCLC
  • Discuss the optimization of I-SABR strategy from stage I to IV NSCLC